Ultravist 370 mg/ml solution for injection and for infusion: detailed information

Patient Information Leaflet

Introduction

Patient Information Leaflet

Ultravist 370 mg/ml solution for injection and infusion

Iopromide

Read the entire leaflet carefully before you start using this medicine, because it contains important information for you.

Keep this leaflet, as you may need to read it again.
If you have any questions, consult your doctor or pharmacist.
This medicine has been prescribed for you only, and you should not give it to others, even if they have the same symptoms as you, because it could harm them.
If you experience any adverse effects, consult your doctor or pharmacist, even if they are adverse effects not listed in this leaflet. See section 4.

Contents of the package leaflet:

What Ultravist is and what it is used for
What you need to know before using Ultravist
How to use Ultravist
Possible side effects
Storage of Ultravist
Contents of the pack and other information

1. What Ultravist is and what it is used for

This medicine is for diagnostic use only.

Ultravist belongs to a group of medicines known as low-osmolar, water-soluble, nephrotropic X-ray contrast media.

Ultravist is used to enhance contrast during imaging of various body areas using certain radiological techniques:

computed tomography (CT, imaging cross-sectional slices or sections of a specific body region)
conventional arteriography (for visualizing arteries), including angiocardiography (visualizing arteries of the heart)
extremity venography (for visualizing veins of the extremities)
intra-arterial/intravenous digital subtraction angiography (DSA)
intravenous urography (for visualizing the urinary tract)
contrast-enhanced mammography (CEM) in adult women to evaluate and detect known or suspected breast lesions, as a complement to mammography (with or without ultrasound) or as an alternative to magnetic resonance imaging (MRI) when MRI is contraindicated or unavailable
arthrography (visualization of joints) and hysterosalpingography (visualization of the uterus and fallopian tubes)

2. What you need to know before using Ultravist

Do not use Ultravist

if you are allergic (hypersensitive) to the active substance or to any of the other components of this medicine (listed in section 6)
if you have clinical hyperthyroidism (your thyroid gland produces too much thyroid hormone)
if you are pregnant or have acute pelvic inflammation and are scheduled to undergo hysterosalpingography (imaging of the uterus and fallopian tubes)

Warnings and precautions

Talk to your doctor or pharmacist before using Ultravist:

If you have ever experienced severe skin rash, skin peeling, blistering and/or oral ulcers after using Ultravist.

Take special care with Ultravist

For all indications

If you have previously experienced an allergic reaction to another iodinated contrast agent, as there is an increased risk of hypersensitivity (allergic) reactions.

The risk of allergic reactions is also higher in patients with a history of bronchial asthma or other allergic disorders, and in patients with known hypersensitivity to Ultravist or any of its excipients.

Your doctor may consider premedication with corticosteroids to minimize allergic reactions.

Patients experiencing such reactions while on beta-blocker therapy may be resistant to treatment with beta-agonists (see "Use with other medicines").

In the event of a severe hypersensitivity reaction, patients with cardiovascular disease (heart disease) are more susceptible to severe, even fatal, reactions.

Due to the possibility of severe hypersensitivity reactions occurring after administration, patients should be observed following completion of the diagnostic procedure.

Severe skin reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP) have been reported with Ultravist. Seek immediate medical attention if you notice any of the signs described in section 4.
If you have thyroid dysfunction (abnormal thyroid function). Inform your doctor if you have hyperthyroidism (overactive thyroid) or goiter (enlargement of the thyroid gland), as iodine-containing contrast agents may induce hyperthyroidism and thyrotoxic crisis (a serious complication of overactive thyroid). You may need a blood test to assess thyroid function and may require medication. Your doctor will consider whether thyroid function tests are necessary before administering Ultravist.

Inform your doctor if you have a history of thyroid disease, including hypothyroidism (underactive thyroid). Abnormal thyroid function blood tests have been reported after imaging with iodine-containing contrast agents, which may indicate possible hypothyroidism or a transient (temporary) reduction in thyroid function, potentially requiring treatment.

Newborns may also be exposed to Ultravist via the mother during pregnancy.

If your child is under 3 years of age:

Your doctor may monitor and check thyroid function, especially in newborns.

If you have central nervous system (CNS) disorders:

Patients with pre-existing central nervous system disorders may have an increased risk of neurological complications related to the administration of Ultravist. Neurological complications are more common during or after cerebral angiography (X-ray imaging of brain vessels) and related procedures.

During or shortly after the imaging procedure, you may experience a short-term brain disorder called encephalopathy. Immediately inform your doctor if you notice any of the signs and symptoms related to this condition described in section 4.

Caution is advised in situations where the seizure threshold is lowered, such as a history of previous seizures or concomitant use of certain medications.

Ultravist must not be administered if you are dehydrated (have not taken in enough fluids). To prevent this, your doctor will ensure you have taken sufficient fluids before your examination (see section "Take special care with Ultravist"). Adequate hydration must be ensured in all patients before intra-arterial or intravenous administration of Ultravist. This is particularly important if you have multiple myeloma (a type of blood cell cancer), diabetes mellitus, excessive urine output (polyuria), reduced urine output (oliguria), hyperuricemia (elevated uric acid levels in blood), and also in newborns, infants, young children, and elderly patients.

Inform your doctor if you have kidney problems. Your doctor will ensure you are well hydrated before your examination. However, intravenous fluid administration (fluid into the veins) is not recommended if you have kidney problems.

Inform your doctor if you have severe kidney problems accompanied by heart disease. Intravenous fluid administration may be dangerous for the heart in such cases.

If you suffer from anxiety:

States of excitement, anxiety, and severe pain may increase the risk or severity of adverse reactions associated with contrast agents. In such cases, inform your doctor, who will attempt to minimize your anxiety.

If you are elderly, as vascular and neurological conditions commonly seen in this population increase the risk of adverse reactions.
If you have a significantly impaired general health condition, your doctor will assess whether the examination is necessary.

Additionally, when Ultravist is administered intra-arterially or intravenously, take particular care in the following situations:

There is a risk that you may develop acute kidney injury after injection (Post-Contrast Acute Kidney Injury (PC-AKI)) following administration of Ultravist. As a result, your kidneys may not function properly for a short period. Some patients may develop renal failure. This is especially relevant if you have any of the following conditions:
pre-existing renal impairment (kidneys not functioning properly). For further information, see section 3: "How to use Ultravist", subsection "Patients with renal impairment",
diabetes mellitus,
dehydration,
multiple myeloma (cancer of blood cells in the bone marrow),
paraproteinemia (a condition characterized by excessive production of certain proteins),
patients receiving high or repeated doses of Ultravist.
If you have severe kidney or liver dysfunction, combined kidney and liver disorders, or are scheduled for liver transplantation. Ultravist will be administered only if absolutely necessary. In such cases, adequate hydration before contrast administration is essential.
If you have diabetes mellitus, as administration of iodinated contrast agents in diabetic patients with pre-existing kidney damage predisposes to renal dysfunction.
If you have cardiovascular disease.

There is an increased risk of clinically significant cardiovascular changes and arrhythmias (abnormal heart rhythms) in patients with significant heart disease or severe coronary artery disease.

Intra-arterial or intravenous injection of contrast medium may precipitate pulmonary edema in patients with heart failure. (See section 3: "How to use Ultravist", subsection "Patients with renal impairment").

If you have been diagnosed with pheochromocytoma (a type of tumor), as you may be at increased risk of developing a hypertensive crisis.
If you have an autoimmune disease (diseases in which the immune system attacks the body's own tissues), as severe cases of vasculitis (inflammation of blood vessels) and Stevens-Johnson-like syndrome (a condition characterized by polymorphic erythema and cutaneous, mucosal, and ocular manifestations) have been reported.
If you have myasthenia gravis (a disease causing muscle weakness and fatigue), as symptoms may worsen.
Caution is required if you have homocystinuria (a disorder of protein metabolism) due to the risk of thrombosis and embolism.
If you have multiple myeloma (a type of blood cell cancer) or Waldenström's paraproteinemia (a condition with excessive production of certain proteins), as you may be more prone to transient renal dysfunction after contrast administration.
Contrast-enhanced mammography exposes you to higher levels of ionizing radiation than conventional mammography, although still within the limits defined by international mammography guidelines. The radiation dose depends on breast thickness and the type of mammographic device used.

Additionally, when Ultravist is used for hysterosalpingography, the following considerations apply:

Pregnancy must be ruled out.
Inflammation of the fallopian tubes may increase the risk of reactions following hysterosalpingography.

Consult your doctor, even if any of the above conditions occurred in the past.

Use of Ultravist with other medicines

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines, including those obtained without a prescription.

Certain medicines may interact with each other. In such cases, it may be necessary to adjust the dose or discontinue treatment with one of the medicines. It is especially important that you inform your doctor if you are taking any of the following medicines:

Metformin (biguanide: a drug used in the treatment of certain forms of diabetes mellitus): in patients with renal impairment, the elimination of biguanides may be reduced, leading to accumulation and development of lactic acidosis (accumulation of lactic acid in the body). Since the use of Ultravist may cause renal impairment or worsen pre-existing renal function, patients treated with metformin may be at increased risk of developing lactic acidosis, particularly those with pre-existing renal impairment. Based on measurements of renal function, the need to discontinue metformin administration should be considered.
Neuroleptics (medicines commonly used to treat psychosis), analgesics (medicines that relieve or eliminate pain), antiemetics (drugs that prevent vomiting or nausea), antihistamines (medicines used to treat allergic rhinitis or dermatitis), and sedatives (tranquilizers). When using these medicines, your seizure threshold may be reduced, thereby increasing your risk of contrast medium-related reactions. Therapy with these drugs should be discontinued 48 hours before contrast administration and not resumed until at least 12 hours after the procedure.
Beta-blockers, as hypersensitivity reactions may be exacerbated, especially in patients with a predisposition to allergies, bronchial asthma, or a history of allergy to other contrast media. In addition, such patients may not respond adequately to standard treatment with beta-agonists.
Interleukin-2, since previous treatments (up to several weeks) with interleukin-2 have been associated with an increased risk of delayed reactions to Ultravist.
Oral cholecystographic contrast media: There is no evidence of interaction with contrast media eliminated via the kidneys.
Diuretics: Due to the risk of dehydration caused by diuretics, your doctor should administer rehydration salts prior to the administration of iodinated contrast medium to minimize the risk of acute renal failure.
Interference with laboratory tests: Iodinated contrast media may interfere with thyroid function tests, as the thyroid gland's ability to bind iodine may be reduced for several weeks.
Radiopharmaceuticals: If you are scheduled to undergo diagnostic or therapeutic procedures for thyroid disorders using radioisotopes, these should be postponed until several weeks after administration of Ultravist, due to reduced radioisotope uptake.

Use of Ultravist with food and drink

You may maintain a normal diet up to two hours before the examination. During the two hours prior to the procedure, you should refrain from eating.

Pregnancy and lactation

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor or pharmacist before using this medicinal product.

Well-controlled studies in pregnant women have not been conducted.

Following diagnostic administration of Ultravist in humans, animal studies do not indicate harmful effects on pregnancy, embryonal/fetal development, parturition, or postnatal development.

The benefit-risk balance should be carefully evaluated before administering an iodinated contrast agent, considering the fetal thyroid sensitivity to iodine, since an acute iodine overload following iodinated contrast administration to the mother may cause fetal thyroid dysfunction.

The safety of Ultravist in women who are breastfeeding has not been investigated. Contrast agents are excreted in breast milk in minimal amounts. Harm to the breastfed infant is not expected.

Driving and use of machines:

Studies on the effects on the ability to drive and operate machinery have not been performed.

Ultravist contains Sodium

This medicinal product contains less than 23 mg of sodium (1 mmol) per dose (based on the average amount administered to a 70 kg individual); therefore, it is essentially “sodium-free”.

3. How to use Ultravist

Follow exactly the administration instructions for this medicine as given by your doctor. If in doubt, consult your doctor or pharmacist again.

Ultravist is a contrast medium used to perform a diagnostic test, which must be carried out in the presence of qualified personnel, preferably under the supervision of a physician, who will provide you with specific instructions throughout the procedure.

Before administering the contrast medium via intraarterial or intravenous route, your doctor must rule out possible renal dysfunction through clinical history and/or laboratory tests.

Contrast-enhanced mammography (CEM): Ultravist will be injected intravenously (a large amount into the vein), preferably using an automatic injector if possible.

Dosage in adults

The recommended doses in adults are as follows:

Indication	Recommended Dose (single injection)	Total Maximum Dose
Conventional arteriography
selective angiocardiography of cardiac chambers	40 – 60 ml	1.5 g I per kg body weight
coronary angiography	5 – 8 ml	1.5 g I per kg body weight
aortic arch angiography	40 – 65 ml	1.5 g I per kg body weight
selective vascular angiography	5 – 12 ml	1.5 g I per kg body weight
retrograde carotid angiography	24 – 32 ml	1.5 g I per kg body weight
Conventional aortography
thoracic	40 – 65 ml	1.5 g I per kg body weight
abdominal	32 – 49 ml	1.5 g I per kg body weight
Extremity arteriography
upper limbs	5 – 10 ml	1.5 g I per kg body weight
lower limbs	16 – 24 ml	1.5 g I per kg body weight
Extremity venography
upper limbs	12 – 24 ml	1.5 g I per kg body weight
lower limbs	24 – 49 ml	1.5 g I per kg body weight
Digital Subtraction Angiography (DSA):
intravenous	30 – 60 ml	1.5 g I per kg body weight	Administration via intraarterial or intravenous route.
Flow rate: 8 - 12 ml/sec in the antecubital vein; 10-20 ml/sec via catheter in the vena cava, only for visualization of major trunk vessels. The amount of contrast medium in the veins can be reduced and still be diagnostic by immediately administering a bolus of isotonic sodium chloride solution afterward.
intraarterial	2 – 20 ml	1.5 g I per kg body weight
In intraarterial DSA, smaller volumes and lower iodine concentrations are sufficient compared to intravenous technique. The more selective the angiography, the lower the contrast medium dose required. Therefore, this method is recommended in patients with impaired renal function.
Computed Tomography (CT)
cranial	1.0 - 1.5 ml/kg body weight	1.5 g I per kg body weight
whole body	1.0 - 1.5 ml/kg body weight	1.5 g I per kg body weight
The required contrast medium doses and their administration rates depend on the organ under study, the diagnostic question, and especially on the scanning and image reconstruction times of the scanners used.
Intravenous urography	0.3 g I/kg body weight = 0.8 ml/kg body weight	1.5 g I per kg body weight
The recommended dose may be increased in obese patients or those with impaired renal function, if considered necessary.
Contrast-enhanced mammography (CEM)	1.5 ml/kg body weight	1.5 g I per kg body weight	Administration via intravenous route.
Arthrography	3 - 15 ml	15 ml	Administration via intraarticular route. Repeated use is not authorized for this indication.
Hysterosalpingography	10 - 25 ml	25 ml	Administration via intrauterine route. Repeated use is not authorized for this indication.

Dosage in special populations

Elderly patients (population over 65 years of age):

Dose adjustment is not required.

Pediatric population (under 18 years of age):

Ultravist must not be used in patients under 18 years of age, as its safety and clinical efficacy have not been established in this group, except that it may be used solely for intravenous urography.

Immature pediatric kidneys require relatively higher doses of the contrast medium, as indicated in the table below:

Intravenous urography	Recommended dose
Neonates (less than 1 month)	1.2 g I/kg body weight = 3.2 ml/kg body weight
Infants (between 1 month and 2 years)	1.0 g I/kg body weight = 2.7 ml/kg body weight
Young children (between 2 and 11 years)	0.5 g I/kg body weight = 1.4 ml/kg body weight
Pediatric population from 11 to 18 years	0.3 g I/kg body weight = 0.8 ml/kg body weight

Infants under 1 year of age, and particularly newborns, are susceptible to disturbances in both blood dynamics and the body's electrolyte balance. Caution must be exercised regarding the dose of contrast medium administered, the technical conduct of the radiological procedure, and the patient's general condition.

Recommended doses in neonates, infants, young children, and pediatric patients aged 11 to 18 years must not be exceeded.

Patients with hepatic impairment:

Dose adjustment is not necessary (see section 2).

Patients with renal impairment:

Since Ultravist is almost exclusively excreted unchanged by the kidneys, elimination of Ultravist is prolonged in patients with renal impairment. To reduce the risk of contrast medium-induced renal injury in patients with pre-existing renal impairment, the lowest possible diagnostic dose should be used (see section 2).

If you think that the effect of Ultravist is too strong or too weak, inform your doctor or pharmacist.

Your doctor will inform you about all aspects related to the administration of Ultravist.

If you use more Ultravist than you should

Symptoms may include hydroelectrolytic imbalance (increase or decrease in total body water and electrolyte levels), renal failure, and cardiovascular and pulmonary complications.

In case of accidental intra-arterial or intravenous overdose, monitoring of hydroelectrolytic balance and renal function is recommended. Treatment of overdose should focus on supporting vital functions. Loss of water and electrolytes should be compensated by infusion. Renal function should be monitored for at least 3 days following the procedure. If necessary, hemodialysis may be used to remove most of the contrast medium from the body.

Ultravist is dialyzable.

In case of overdose or accidental ingestion, contact the Toxicology Information Service; Telephone 91 562 04 20.

If you have any further questions about the use of this product, ask your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, this medicine may cause adverse effects, although not everyone will experience them.

The overall safety profile of Ultravist is based on data from pre-marketing studies involving more than 3,900 patients, post-authorization studies in over 74,000 patients, as well as spontaneous reporting data and published literature.

The most frequently observed adverse reactions in patients receiving Ultravist are headache, nausea, and dilation of blood vessels.

The most serious adverse reactions observed in patients receiving Ultravist are anaphylactic shock, respiratory arrest, narrowing or obstruction of the bronchi, fluid accumulation in the larynx and pharynx, asthma, coma, cerebral infarction, stroke, fluid accumulation in the brain, convulsions, abnormal heart rhythms, cardiac arrest, myocardial ischemia, myocardial infarction, heart failure, decreased heart rate, bluish discoloration of the skin and mucous membranes, low blood pressure, shock, difficulty breathing, fluid accumulation in the lungs, respiratory failure, and aspiration.

All indications

Frequent adverse effects (may affect between 1 and 10 out of every 100 patients):

dizziness, headache, altered taste
- blurred vision, visual disturbances
- chest pain or discomfort
- high blood pressure, dilation of blood vessels
- vomiting, nausea
- pain, reactions at injection site (e.g., pain, and frequently unknown sensation of warmth, fluid accumulation, swelling, and injury) and sensation of warmth.

Uncommon adverse effects (may affect between 1 and 10 out of every 1,000 patients):

allergic reactions (hypersensitivity/anaphylactoid reactions, e.g., fluid accumulation in the face, sneezing, cough, fluid accumulation in mucous membranes, hives, itching, rapid swelling of the skin and mucous membranes; frequency not known and *: anaphylactic shock, respiratory arrest, and asthma; *: narrowing or obstruction of the bronchi, fluid accumulation in larynx or pharynx; frequency not known: fluid accumulation in the tongue, pharyngeal or laryngeal spasm, conjunctivitis, lacrimation, rhinitis, hoarseness, and throat irritation)
fainting, confusion, nervousness, sensory disturbances, decreased sensation, drowsiness
abnormal heart rhythms (arrhythmias, *)
low blood pressure (*)
difficulty breathing (*)
abdominal pain
fluid accumulation (edema)

Rare adverse effects (may affect between 1 and 10 out of every 10,000 patients):

anxiety
cardiac arrest (*), myocardial ischemia (*), palpitations

Adverse effects of unknown frequency (frequency cannot be estimated from available data):

thyrotoxic crisis (acute worsening of thyroid gland function), thyroid disorder
coma (*), cerebral ischemia or stroke (*), stroke (*), fluid accumulation in the brain (*, only with intra-arterial or intravenous administration), convulsion (*), total or partial vision loss in one eye (only with intra-arterial or intravenous administration), loss of consciousness, agitation, memory loss, tremor, speech disorders, paresis/paralysis, contrast-induced encephalopathy
hearing disorders
myocardial infarction (*), heart failure (*), decreased heart rate (*), increased heart rate, bluish discoloration of the skin and mucous membranes (*)
shock (*), decreased perfusion due to arterial obstruction (only with intra-arterial or intravenous administration), arterial constriction (only with intra-arterial or intravenous administration)
fluid accumulation in the lungs (*), respiratory failure (*), aspiration (*)
difficulty breathing, enlargement of the salivary glands, diarrhea
bullous skin reactions (e.g., Stevens-Johnson syndrome or Lyell's syndrome), skin discoloration and appearance changes, skin rash, excessive sweating, acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms (DRESS)
compartment syndrome in case of extravasation (only with intra-arterial or intravenous administration)
renal failure (only with intra-arterial or intravenous administration), acute renal failure (only with intra-arterial or intravenous administration)
- general malaise, chills, pallor
- fluctuations in body temperature

* Cases have been reported that were life-threatening.

If you consider any of the adverse effects you experience to be severe, or if you notice any adverse effects not listed in this leaflet, inform your doctor or pharmacist.

Seek immediate medical assistance if you experience any of the following signs and symptoms (frequency unknown):

Reddish patches on the trunk, appearing as macules with target-like or circular shapes, often with central blisters, skin peeling, and ulcers in the mouth, throat, nose, genitals, and eyes. These severe skin rashes may be preceded by fever and flu-like symptoms (Stevens-Johnson syndrome, toxic epidermal necrolysis).
Widespread rash, high body temperature, and enlarged lymph nodes (DRESS syndrome or drug hypersensitivity syndrome).
Generalized, red, peeling rash with bumps under the skin and blisters accompanied by fever following the imaging procedure (acute generalized exanthematous pustulosis).

Short-term brain disorder (encephalopathy) that may cause memory loss, confusion, hallucinations, vision problems, vision loss, seizures, loss of coordination, paralysis on one side of the body, speech difficulties, and fainting.

Class effects

Imaging with contrast medium is performed under general anesthesia in some selected patients. However, a high incidence of adverse reactions has been reported in these patients, attributed to the patient's inability to distinguish between true adverse reactions and the effects of low-dose anesthesia, which prolongs circulation time and increases the duration of exposure to the contrast medium.

Reporting of adverse effects

If you experience any type of adverse effect, consult your doctor or radiologist, even if it is an effect not listed in this leaflet. You may also report them directly through the Spanish Pharmacovigilance System for Human Medicines: https://www.notificaram.es. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Ultravist

Keep this medicine out of the sight and reach of children.

Store in the original packaging to protect from light and X-rays.

Do not store above 30°C.

Do not use this medicine after the expiry date stated on the container after EXP.

Ultravist is supplied as a clear, colourless to pale yellow solution for injection. Do not use Ultravist if you notice significant changes in colour, the appearance of particles in suspension, or if the container is damaged.

Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines and packaging that you no longer need. This will help protect the environment.

6. Contents of the pack and other information

Composition of Ultravist 370

The active substance is iopromide. 1 ml of injectable solution contains 769 mg of iopromide, equivalent to 370 mg of iodine.

1 vial containing 50 ml of injectable solution contains 38.45 g of iopromide, equivalent to 18.5 g of iodine.
1 vial containing 100 ml of injectable solution contains 76.9 g of iopromide, equivalent to 37 g of iodine.
1 vial containing 200 ml of injectable solution contains 153.8 g of iopromide, equivalent to 74 g of iodine.
1 vial containing 500 ml of injectable solution contains 384.5 g of iopromide, equivalent to 185 g of iodine.

The other components are: calcium edetate and sodium, tromethamine, hydrochloric acid (10% diluted) (to adjust pH), sodium hydroxide (to adjust pH), and
water for injections.

Appearance of the product and contents of the pack

Ultravist 370 is supplied as a clear, ready-to-use injectable and infusion solution, colourless to pale yellow. Each container contains: vials of 50 ml, 100 ml (single-dose) or 200 ml, 500 ml (multi-dose).

Pack sizes:

1 vial of 50 ml, 100 ml (single-dose) or 200 ml, 500 ml (multi-dose).
8 vials of 500 ml (multi-dose).
10 vials of 200 ml (multi-dose).

Only certain pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder:

Bayer Hispania, S.L.
Avda. Baix Llobregat, 3-5
08970 Sant Joan Despí (Barcelona)
Spain

Manufacturer

The manufacturer can be identified by the batch number printed on the carton and on the label of each vial:

If the first and second characters are MA, the manufacturer is:
Berlimed S.A.
Polígono Industrial Santa Rosa
C/ Francisco Alonso, s/n
28806 Alcalá de Henares (Madrid) – Spain
If the first and second characters are KT, the manufacturer is:
Bayer AG
Müllerstrasse 178
13353 Berlin, Germany

Date of the most recent revision of this leaflet: September 2023

Detailed information on this medicinal product is available on the website of the Spanish Agency of Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.

This information is intended for healthcare professionals only (see also section 3: How to use Ultravist)

Indications

This medicinal product is for diagnostic use only.

Ultravist 370 mg/ml is indicated for contrast enhancement in computed tomography (CT), conventional angiography including angiocardiography, extremity venography, digital subtraction angiography (DSA), intravenous urography, arthrography, hysterosalpingography, and contrast-enhanced mammography in adult women to evaluate and detect known or suspected breast lesions, as an adjunct to mammography (with or without ultrasound) or as an alternative to magnetic resonance imaging (MRI) when MRI is contraindicated or unavailable.

Before injection

Ultravist must be warmed to body temperature prior to administration.

The contrast medium should be inspected visually before use and must not be administered if there is any change in colour, visible particles in suspension (including crystals), or if the container is damaged.

Handling

Vials (≤ 100 ml)

The contrast medium solution should not be drawn into a syringe, nor should the vial be connected to an infusion set, until immediately before the procedure.

The rubber stopper should not be punctured more than once to avoid introducing large quantities of microparticles from the stopper into the solution. Long-tip cannulae with a maximum diameter of 18 G are recommended for puncturing the stopper and withdrawing the contrast medium (special extraction cannulae with a side opening are particularly suitable).

Any unused contrast medium remaining after administration to a patient must be discarded. Disposal of unused medicinal product and all materials that have come into contact with it must be carried out in accordance with local regulations.

Large-volume containers (≥ 200 ml, for intra-arterial or intravenous administration only)

Multiple withdrawals of contrast medium must be performed using equipment authorized for multiple administration. Auto-injectors/pumps must not be used in small children.

The rubber stopper of the vial must not be punctured more than once to prevent large quantities of microparticles from the stopper entering the solution.

The contrast medium must be administered using an automatic injector or another approved method that ensures sterility of the contrast medium.

The patient tubing (injector-to-patient tubing) must be replaced for each patient to prevent possible contamination.

Connecting tubes and all disposable parts of the injection system must be discarded when the infusion vial is empty.

Any remaining contrast medium solution in the vial, connecting tubes, or any other part of the disposable components of the injection system must be discarded 10 hours after the first opening of the container.

It is essential to follow the supplementary instructions provided by the manufacturers of the respective materials used.

Contrast medium remaining in an opened Ultravist container must be discarded 10 hours after the container has been opened. Disposal of unused medicinal product and all materials that have come into contact with it must be carried out in accordance with local regulations.